SEC Form SC 13G filed by UroGen Pharma Ltd.

11/6/24 1:50:55 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $URGN alert in real time by email

SC 13G 1 UroGenPharmaLtdURGN.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* UroGen Pharma Ltd. ----------------------------------------------------- (Name of Issuer) Ordinary Shares ----------------------------------------------------- (Title of Class of Securities) M96088105 ----------------------------------------------------- (CUSIP Number) September 30, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.M96088105 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 2,149,093 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 2,172,327 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 2,172,327 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 5.2% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.M96088105 13G Page 3 of 5 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: UroGen Pharma Ltd. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 ISRAEL -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway, New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Ordinary Shares -------------------------------------------------------------- (e) CUSIP Number: M96088105 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.M96088105 13G Page 4 of 5 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of September 30, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.M96088105 13G Page 5 of 5 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 06, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY

Get the next $URGN alert in real time by email

Date

Price Target

Rating

Analyst

8/22/2024

$40.00

Buy

Guggenheim

2/8/2023

$35.00 → $10.00

Buy → Hold

Jefferies

4/27/2022

$20.00

Buy

Berenberg

1/18/2022

$50.00 → $34.00

Buy

HC Wainwright & Co.

SEC Form SC 13G filed by UroGen Pharma Ltd.

Chat with this insight

Recent Analyst Ratings for $URGN

$URGN Leadership Updates

Live Leadership Updates

UroGen Appoints Chris Degnan as Chief Financial Officer

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

NorthStar Appoints Peter Pfreundschuh to Board of Managers

$URGN Press Releases

Fastest customizable press release news feed in the world

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

$URGN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on UroGen Pharma with a new price target

UroGen Pharma downgraded by Jefferies with a new price target

Berenberg initiated coverage on UroGen Pharma with a new price target

$URGN SEC Filings

SEC Form 10-Q filed by UroGen Pharma Ltd.

UroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 8-K filed by UroGen Pharma Ltd.

$URGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$URGN Market Insights

Live Market Insights

SEC Form 4 filed by Chief Financial Officer Degnan Chris

SEC Form 3 filed by new insider Degnan Chris

Chief Medical Officer Schoenberg Mark converted options into 1,666 units of Ordinary Shares and sold $11,236 worth of Ordinary Shares (859 units at $13.08), increasing direct ownership by 0.56% to 145,091 units (SEC Form 4)

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target

NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

On Monday, UroGen Pharma Priced The Public Offering Of 5M Shares At $17.50/Share, Pre-funded Warrants To Purchase 1.14M Shares At $17.499/Pre-funded Warrant, With Gross Proceeds Of Approximately $107.5M

$URGN Financials

Live finance-specific insights

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

$URGN Large Ownership Changes

This live feed shows all institutional transactions in real time.